Caracterización clínico epidemiológico del cáncer de mama Triple Negativo Centro De Atención al Paciente Oncológico III Congreso
Keywords:
carcinoma, neoplasias inflamatorias de la mama, mujerAbstract
Introduction: Triple-negative breast cancer (TNBC) corresponds to a heterogeneous group of tumors defined by the absence of estrogen and progesterone hormone receptors and the lack of expression of human epidermal growth factor 2 (HER-2). Objective: To characterize patients diagnosed with triple-negative breast cancer treated at the Hospital III Congreso Cancer Patient Care Center in Pinar del Río province during the period 2018-2020. Method: A descriptive cross-sectional study was conducted. The sample consisted of 62 patients diagnosed with histologically confirmed triple-negative breast cancer. The variables considered were age, skin color, histological variant, tumor size, lymph node status, vascular and lymphatic invasion, histological and nuclear grade, clinical stages, and treatment. Descriptive statistics were used, and distributions were determined in frequencies and percentages. Tables were created for a better understanding of the results. Results: The predominant age group was 60 years and older, with white skin color, the most frequent histological diagnosis was infiltrating ductal carcinoma, clinical stage II prevailed, axillary lymph node involvement and non-vascular and lymphatic invasion predominated, and surgery followed by chemotherapy were the most frequently used treatments.
Downloads
References
1 Cauna-Orocollo Y, Córdova-Salazar AA, Campos-Tineo J Modelos murinos para el estudio de cáncer de mama triple negativo . Rev Fac Med Hum. 2023;23(4):150-157. doi 10.25176/RFMH.v23i4.6206
2 Heredia-Martínez B, González-Fernández H. Caracterización del cáncer de mama triple negativo. Revista Finlay [revista en Internet]. 2020 [citado 2020 Oct 2]; 10(3):[aprox. 9 p.]. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/850
3Abreu Quedi B, Montiel-Jarolin DJ, Duarte-Dávalos R, Barreto Román SA. Cáncer de mama triple negativo con metástasis interescapular. Rev. cient. cienc. salud 2023; 5: e5205.
4. Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer who should receive neoadjuvant chemotherapy? Surg Oncol Clin N Am. 2018;27:141-53. DOI: http://dx.doi.org/10.1016/j.soc.2017.08.004
5. Zaharia M, Gómez H. Cáncer de mama triple negativo: una enfermedad de difícil diagnóstico y tratamiento. Rev Perú Med Exp Salud Pública. 2013;30(4):649-56. Revista Cubana de Oncología. 2020 (Sep-Dic);18(3):e_45
19
6. A Caziuc, D Schlanger, G Amarinei and G Calin Dindelegan. Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer? J. Clin. Med. 2019, 8, 545; doi:10.3390/jcm8040545. Disponible en: www.mdpi.com/journal/jcm
7. Keenan T, Moy V, Mroz E A, Ross K, Niemierko A, Rocco JW, et al. Comparison of de genomic landscape between primary breast cancer in african american versus white woman and the association off racial differences with tumor recurrence. J Clin Oncol. 33:3621-7. DOI: http://dx.doi.org/10.1200/JCO.2015.62.2126
8. Quirós Alpízar JL, Espinoza Morales K. Supervivencia a 5 años de pacientes con cáncer de mama triple negativo. Med Legal Costa Rica. 2017 [acceso 20/06/2020];34(1):59-72. Disponible en: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-
9. Marcheco-Teruel B, Parra EJ, Fuentes-Smith E, Salas A, Buttenschøn HN, Demontis D, et al. Cuba: exploring the history of admixture and the genetic basis of pigmentation using autosomal and uniparental markers. PLos Genetics. 2014;10(7):e1004488. DOI: http://dx.doi.org/10.1371/journal.pgen.1004488.
10. Pardo C, de Vries E. Supervivencia global de pacientes con diagnóstico de cáncer de mama del Instituto Nacional de Cancerología (INC). Rev Colomb Cancerol. 2017 [acceso 20/06/2020];21(1):12-18. Disponible en: http://www.scielo.org.co/pdf/rcc/v21n1/0123-9015-rcc-21-01-00012.pdf.
11. Saldañas. After Chemotherapy, Fatigue May Contribute More to Balance Problems Than Neuropathy. After receiving chemotherapy for breast cancer, women who had more severe, persistent fatigue were more likely to have balance problems, whether they had peripheral neuropathy or not. 2022 [acceso 20/06/2020];34(1):59-72. Disponible en: http://www.breaastcancer.org/es/noticias-de-investigación
12. Joyce DP, Murphy D, Lowery AJ, Curran C, Barry K, Malone C, et al. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer. Surgeon. 2017;15:272-7. DOI: http://dx.doi.org/10.1016/j.surge.2016.10.001
13. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol. 2018;25:S142-50. DOI: https://doi.org/10.3747/co.25.3954.
14. Kaplan HG, Malmgren JA, Atwood MK. Triple-negative breast cancer in the elderly: prognosis and treatment. Breast J. 2017;23:630–7. DOI: https://doi.org/10.1111/tbj.12813.
15. Swain SM, Jeong JH, Geyer Jr CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362:2053-65. DOI: https://doi.org/10.1056/NEJMoa0909638.
16. Hea MY, Rancoulea Ch, Rehailia-Blancharda A, Espenel S, Trone JC, Bernichon E, et al. Radiotherapy in triple-negative breast cancer: current situation and Revista Cubana de Oncología. 2020 (Sep-Dic);18(3):e_45
22 upcoming strategies. Crit Rev Oncol Hematol. 2018;131:96-101. DOI: https://doi.org/10.1016/j.critrevonc.2018.09.004.
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aida Rosa Díaz Crespo, María de la Caridad Casanova Moreno, Deysi Lucia Sánchez Hernández, Noel Rodríguez Cuba, Eveline García Espinosa
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
